Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
IN8bio, Inc. announced operational and financial highlights for Q2 2021, reporting significant progress in its Phase 1 clinical trials for INB-200 and INB-100. The successful completion of the first cohort treatment in both trials demonstrates strong potential in solid tumors and leukemia. Following a $40M IPO in August 2021, the company bolstered its cash position to $32.6M. However, IN8bio recorded a net loss of $3.1M for the quarter, with R&D expenses rising to $2.1M, indicating ongoing investment in its clinical programs.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at two virtual events: NewYorkBIO Virtual Breakfast Series on August 31 at 9 am EDT, and H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-14. The presentations will highlight the company's innovative gamma-delta T-cell therapies using its DeltEx platform. The H.C. Wainwright presentation will be available for 90 days post-release. IN8bio is currently conducting Phase 1 clinical trials for its lead product candidates targeting glioblastoma and leukemia.
IN8bio has completed dosing for the first cohort in a Phase 1 clinical trial of INB-100, a gamma-delta T-cell therapy for leukemia patients undergoing haploidentical stem cell transplant. No severe adverse infusion reactions or dose limiting toxicities were reported among the three patients. The first two patients remain in complete remission over one year post-dosing. The trial aims to evaluate safety, tolerability, and overall survival, with topline data expected in 2023. IN8bio focuses on innovative T-cell therapies to improve treatment outcomes for leukemia and other cancers.
IN8bio (Nasdaq: INAB) has appointed Emily Fairbairn and Luba Greenwood to its Board of Directors. Both appointees bring extensive experience in the biopharmaceutical and life sciences sectors. Fairbairn, an influential investor and former CEO of Ascend Capital, focuses on corporate governance, while Greenwood's background includes leadership roles at Google Life Sciences and Roche. Their terms will end at the 2022 annual stockholders' meeting. IN8bio aims to advance its clinical-stage gamma-delta T-cell therapies for cancer treatment, utilizing its innovative DeltEx platform.
IN8bio, Inc. (Nasdaq: INAB) has announced the pricing of its initial public offering (IPO) at $10 per share, totaling gross proceeds of $40 million before expenses. The offering consists of 4,000,000 shares and is expected to close on August 3, 2021. Additionally, an underwriter option allows for 600,000 more shares to be purchased. IN8bio specializes in gamma-delta T cell therapies for cancer treatment and is currently conducting Phase 1 trials for its lead candidates targeting glioblastoma and leukemia.